BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gegg ME, Menozzi E, Schapira AH. Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments. Neurobiology of Disease 2022;166:105663. [DOI: 10.1016/j.nbd.2022.105663] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Navarro-Romero A, Fernandez-Gonzalez I, Riera J, Montpeyo M, Albert-Bayo M, Lopez-Royo T, Castillo-Sanchez P, Carnicer-Caceres C, Arranz-Amo JA, Castillo-Ribelles L, Pradas E, Casas J, Vila M, Martinez-Vicente M. Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology. NPJ Parkinsons Dis 2022;8:126. [PMID: 36202848 DOI: 10.1038/s41531-022-00397-6] [Reference Citation Analysis]
2 Santana AG, Robinson K, Vickers C, Deen MC, Chen H, Zhou S, Dai B, Fuller M, Boraston AB, Vocadlo DJ, Clarke LA, Withers SG. Pharmacological Chaperones for GCase that Switch Conformation with pH Enhance Enzyme Levels in Gaucher Animal Models. Angew Chem Int Ed 2022;61. [DOI: 10.1002/anie.202207974] [Reference Citation Analysis]
3 Boddupalli CS, Nair S, Belinsky G, Gans J, Teeple E, Nguyen TH, Mehta S, Guo L, Kramer ML, Ruan J, Wang H, Davison M, Kumar D, Vidyadhara DJ, Zhang B, Klinger K, Mistry PK. Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy. Elife 2022;11:e79830. [PMID: 35972072 DOI: 10.7554/eLife.79830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cavallieri F, Fioravanti V, Bove F, Del Prete E, Meoni S, Grisanti S, Zedde M, Pascarella R, Moro E, Valzania F. COVID-19 and Parkinsonism: A Critical Appraisal. Biomolecules 2022;12:970. [DOI: 10.3390/biom12070970] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Engelender S, Stefanis L, Oddo S, Bellucci A. Can We Treat Neurodegenerative Proteinopathies by Enhancing Protein Degradation? Mov Disord 2022. [PMID: 35579450 DOI: 10.1002/mds.29058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Boddupalli CS, Nair S, Belinsky G, Gans J, Teeple E, Nguyen T, Mehta S, Guo L, Kramer ML, Ruan J, Wang H, Davison M, Vidyadhara D, Bailin Z, Klinger K, Mistry PK. Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells.. [DOI: 10.1101/2022.05.13.491834] [Reference Citation Analysis]